Compositions and methods for viral sensitization

Patent metadata

Field	Value
Publication number	US-11339146-B2
Application number	US-202016877291-A
Country	US
Kind code	B2
Filing date	May 18, 2020
Priority date	Jan 26, 2015
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

First claim

What is claimed is:

1. A method for enhancing or increasing viral production in cells comprising, administering a compound of Formula (V):

or a pharmaceutically acceptable salt, or a stereochemically isomeric form thereof,
wherein:
X 7 is H, substituted or unsubstituted aryl or heteroaryl; substituted or unsubstituted, linear or branched alkyl, alkenyl, or alkynyl; or substituted or unsubstituted cycloalkyl.

2. The method of claim 1 , wherein X 7 is substituted or unsubstituted alkylamine.

3. The method of claim 1 , wherein the compound is of formula:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the cells are cultured cells, adherent or suspension cells, cancer cells, tumor cells or cells which have been immortalized, primary cells, non-immortalized cells, normal cells, eggs, or egg cells contained within or derived from embryonated eggs.

5. The method of claim 4 , wherein the cells are cancer cells or non-cancer cells in vitro or in ovo.

6. The method of claim 1 , wherein enhancing or increasing viral production comprises one or more of enhancing or increasing the infection of cells or a rate thereof, enhancing or increasing reproductive capacity of a virus or a rate thereof, enhancing or increasing spread or titerof a virus or a rate at which full titer may be reached, enhancing or increasing antigen expression from a virus or a rate thereof, enhancing or increasing gene or transgene expression from a virus or a rate thereof, enhancing or increasing virus protein expression in cells or a rate thereof, or any combination thereof.

7. The method of claim 6 , wherein enhancing or increasing viral production comprises one or more of enhancing or increasing the infection of cells or a rate thereof.

8. The method of claim 6 , wherein enhancing or increasing viral production comprises one or more of enhancing or increasing reproductive capacity of a virus or a rate thereof.

9. The method of claim 6 , wherein enhancing or increasing viral production comprises enhancing or increasing spread or titer of a virus or a rate at which full titer may be reached.

10. The method of claim 6 , wherein enhancing or increasing viral production comprises enhancing or increasing antigen expression from a virus or a rate thereof.

11. The method of claim 6 , wherein enhancing or increasing viral production comprises enhancing or increasing gene or transgene expression from a virus or a rate thereof.

12. The method of claim 1 , wherein X 7 is substituted or unsubstituted C 1 -C 12 alkyl.

13. The method of claim 1 , wherein X 7 is substituted or unsubstituted cycloalkyl.

14. The method of claim 1 , wherein X 7 is substituted benzyl.

15. The method of claim 1 , wherein X 7 is unsubstituted phenyl.

16. The method of claim 1 , wherein X 7 is substituted phenyl.

Assignees

• Ottawa Hospital Res Inst
• Univ Ottawa
• Ottawa Hospital Research Institute And Univ Of Ottawa

Inventors

• Diallo Jean-Simon
• Boddy Christopher Noyce
• Dornan Mark
• Krishnan Ramya
• Arulanandam Rozanne
• Le Boeuf Fabrice
• Smith Jeffrey
• Macklin Andrew

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N2760/20252

  relating to complementing cells and packaging systems for producing virus or viral particles · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2760/16152

  relating to complementing cells and packaging systems for producing virus or viral particles · CPC title